Medical Doctor Program year 2023 Reported 2020–2023 Source: CMS Open Payments, 2026 publication

Daniel Meador

Internal Medicine Sonora, CA Medical Doctor

NPI 1619925989 CMS profile 751209

782 Delnero Dr, Sonora, CA 95370

Open in the dashboard

General payments

$42

2 records reported · program years 2020–2023

Research payments

$0

Paid to them · None reported · program years 2020–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Daniel Meador of Sonora, CA is reported in the CMS Open Payments database as having received $42 across 2 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 16th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $25 1
2020 General $18 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Meador
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Daniel Meador were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Daniel Meador Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $18 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $25 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2020–2023
  1. Sumitomo Pharma America, Inc. $25 1 payment
  2. Sunovion Pharmaceuticals Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2023
  1. Food and Beverage $42 2 payments
Products named General payments · program years 2020–2023
  1. GEMTESA $25 1 payment
  2. LONHALA MAGNAIR $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 243 drugs

Part D claims

20,870

Median for Hospitalist: 109

Drug cost

$1,506,382

Median for Hospitalist: $6,399

Branded share of claims

27.7%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 108 $454,867
Eliquis Apixaban Brand 844 $232,176
Jardiance Empagliflozin Brand 186 $51,375
Xarelto Rivaroxaban Brand 179 $50,176
Ozempic Semaglutide Brand 30 $31,502
Januvia Sitagliptin Phosphate Brand 103 $30,135
Dupixent Syringe Dupilumab Brand 13 $26,368
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 77 $23,830
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 36 $22,436
Trulicity Dulaglutide Brand 35 $19,374

The 10 drugs with the highest cost, of 243 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$485,736

Medicare's payments for the services billed

Medicare patients

679

Average age 79

Services billed

5,977

384 women, 295 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 48%
Arthritis 47%
Depression 45%
Heart failure 42%
Atrial fibrillation 38%
Ischemic heart disease 37%
Alzheimer's or dementia 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

2 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record